
Shattuck Labs (STTK) Stock Forecast & Price Target
Shattuck Labs (STTK) Analyst Ratings
Bulls say
Shattuck Labs Inc. is strategically positioned in the biotechnology sector with its development of innovative treatments for inflammatory bowel disease (IBD), specifically through its main program SL-325, a potential first-in-class DR3 antagonist antibody. The reported increase in the use of biologics among patients with Crohn's disease (CD) from 22% to 44% and ulcerative colitis (UC) from 5% to 16% between 2007 and 2015 illustrates a growing market for biologic therapies, which could contribute to substantial demand for Shattuck Labs's products. Furthermore, the optimistic projections for market share growth, supported by a focus on strong efficacy and safety profiles, suggest solid commercial prospects for SL-325 and its extended half-life counterpart, SL-425.
Bears say
Shattuck Labs Inc. faces a negative outlook primarily due to the potential inefficacy of its lead programs, including SL-325 and SL-425, which may not meet clinical response or safety standards necessary for successful market introduction. Additionally, the consistently underestimated market growth and therapy adoption rates in inflammatory bowel disease (IBD) could lead to reduced demand for the company's products in a competitive landscape. Lastly, any significant immunogenicity issues or adverse safety signals emerging during trials could hinder product development and limit commercial uptake, further exacerbating the company's financial challenges.
This aggregate rating is based on analysts' research of Shattuck Labs and is not a guaranteed prediction by Public.com or investment advice.
Shattuck Labs (STTK) Analyst Forecast & Price Prediction
Start investing in Shattuck Labs (STTK)
Order type
Buy in
Order amount
Est. shares
0 shares